SKYE vs. MIRM, CALT, PRTA, DAWN, ABCL, LQDA, TYRA, COLL, INVA, and CVAC
Should you be buying Skye Bioscience stock or one of its competitors? The main competitors of Skye Bioscience include Mirum Pharmaceuticals (MIRM), Calliditas Therapeutics AB (publ) (CALT), Prothena (PRTA), Day One Biopharmaceuticals (DAWN), AbCellera Biologics (ABCL), Liquidia (LQDA), Tyra Biosciences (TYRA), Collegium Pharmaceutical (COLL), Innoviva (INVA), and CureVac (CVAC). These companies are all part of the "pharmaceutical preparations" industry.
Skye Bioscience (NASDAQ:SKYE) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, community ranking, valuation and profitability.
Skye Bioscience has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -69.67%. Mirum Pharmaceuticals' return on equity of -56.46% beat Skye Bioscience's return on equity.
Mirum Pharmaceuticals received 109 more outperform votes than Skye Bioscience when rated by MarketBeat users. However, 100.00% of users gave Skye Bioscience an outperform vote while only 72.55% of users gave Mirum Pharmaceuticals an outperform vote.
21.1% of Skye Bioscience shares are owned by institutional investors. 0.7% of Skye Bioscience shares are owned by insiders. Comparatively, 22.9% of Mirum Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Skye Bioscience currently has a consensus price target of $22.00, indicating a potential upside of 120.44%. Mirum Pharmaceuticals has a consensus price target of $49.73, indicating a potential upside of 94.63%. Given Skye Bioscience's higher possible upside, equities research analysts plainly believe Skye Bioscience is more favorable than Mirum Pharmaceuticals.
In the previous week, Mirum Pharmaceuticals had 6 more articles in the media than Skye Bioscience. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 2 mentions for Skye Bioscience. Mirum Pharmaceuticals' average media sentiment score of 0.34 beat Skye Bioscience's score of -0.67 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.
Skye Bioscience has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500.
Skye Bioscience has higher earnings, but lower revenue than Mirum Pharmaceuticals.
Summary
Mirum Pharmaceuticals beats Skye Bioscience on 10 of the 16 factors compared between the two stocks.
Get Skye Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SKYE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skye Bioscience Competitors List
Related Companies and Tools
